Saad Shakir

7.8k total citations · 1 hit paper
147 papers, 4.9k citations indexed

About

Saad Shakir is a scholar working on Toxicology, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Saad Shakir has authored 147 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Toxicology, 32 papers in Pharmacology and 24 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Saad Shakir's work include Pharmacovigilance and Adverse Drug Reactions (35 papers), Pharmaceutical studies and practices (21 papers) and SARS-CoV-2 and COVID-19 Research (13 papers). Saad Shakir is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (35 papers), Pharmaceutical studies and practices (21 papers) and SARS-CoV-2 and COVID-19 Research (13 papers). Saad Shakir collaborates with scholars based in United Kingdom, United States and Netherlands. Saad Shakir's co-authors include Lorna Hazell, Lynda V. Wilton, Deborah Layton, Lynda Wilton, A. Boshier, Pipasha Biswas, Emma Heeley, Gideon Koren, Adrienne Einarson and Victoria Cornelius and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Saad Shakir

138 papers receiving 4.6k citations

Hit Papers

Under-Reporting of Adverse Drug Reactions 2006 2026 2012 2019 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Under-Reporting of Adverse Drug Reactions
    2006 1.4k citations Lorna Hazell, Saad Shakir Drug Safety profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Saad Shakir United Kingdom 33 1.7k 1.0k 869 649 645 147 4.9k
Gianluca Trifirò Italy 46 1.4k 0.8× 986 0.9× 821 0.9× 795 1.2× 446 0.7× 270 7.0k
Eugène van Puijenbroek Netherlands 33 2.4k 1.4× 816 0.8× 1.0k 1.2× 353 0.5× 475 0.7× 248 4.8k
Maryse Lapeyre‐Mestre France 46 1.5k 0.9× 1.4k 1.4× 1.3k 1.5× 1.2k 1.9× 1.6k 2.5× 435 9.0k
Alexandre Pariente France 46 1.2k 0.7× 420 0.4× 977 1.1× 1.0k 1.6× 404 0.6× 296 8.1k
Ron M. C. Herings Netherlands 47 569 0.3× 675 0.6× 1.1k 1.2× 803 1.2× 518 0.8× 247 8.4k
Annie Fourrier‐Réglat France 31 916 0.5× 361 0.3× 799 0.9× 528 0.8× 255 0.4× 125 3.7k
Inés Ruiz Chile 10 1.3k 0.8× 1.5k 1.4× 2.2k 2.5× 1.2k 1.9× 293 0.5× 18 8.6k
E A Roberts Canada 19 1.3k 0.8× 1.5k 1.4× 2.1k 2.4× 1.2k 1.8× 299 0.5× 34 9.5k
Bernard Bégaud France 34 565 0.3× 448 0.4× 1.1k 1.3× 1.3k 2.0× 356 0.6× 179 6.8k
E Janecek Canada 5 1.3k 0.8× 1.5k 1.4× 2.1k 2.4× 1.2k 1.8× 306 0.5× 8 8.5k

Countries citing papers authored by Saad Shakir

Since Specialization
Citations

This map shows the geographic impact of Saad Shakir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saad Shakir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saad Shakir more than expected).

Fields of papers citing papers by Saad Shakir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saad Shakir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saad Shakir. The network helps show where Saad Shakir may publish in the future.

Co-authorship network of co-authors of Saad Shakir

This figure shows the co-authorship network connecting the top 25 collaborators of Saad Shakir. A scholar is included among the top collaborators of Saad Shakir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saad Shakir. Saad Shakir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roy, Debabrata, et al.. (2025). Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective. British Journal of Clinical Pharmacology. 91(5). 1352–1360. 3 indexed citations
2.
Evans, Alison, et al.. (2025). Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study. BMJ Open. 15(5). e093366–e093366. 1 indexed citations
3.
Hussain, Zahid, Saad Shakir, Syeda Abida Ejaz, et al.. (2024). Exploration of newly synthesized deferasirox derivatives as potential anti-cancer agents via in-vitro and in-silico approaches. International Journal of Biological Macromolecules. 283(Pt 4). 137971–137971. 1 indexed citations
4.
5.
6.
Hunsel, Florence van, Nicolas H. Thurin, C. Dureau‐Pournin, et al.. (2023). Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose. Drug Safety. 46(4). 391–404. 14 indexed citations
7.
8.
Lane, Samantha, Alison Yeomans, & Saad Shakir. (2022). Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. BMJ Open. 12(7). e060425–e060425. 12 indexed citations
9.
Rodrı́guez, Luis A. Garcı́a, Mari‐Ann Wallander, Leif Friberg, et al.. (2020). Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice. Expert Opinion on Drug Safety. 19(11). 1513–1520. 4 indexed citations
10.
Osborne, Vicki, et al.. (2020). Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?. BMJ evidence-based medicine. 27(1). 1–6. 27 indexed citations
11.
Shakir, Saad. (2020). Cytokine storms: a major killer in patients with severe COVID-19 infection. 2 indexed citations
12.
13.
Behr, Elijah R., et al.. (2017). Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. BMJ Open. 7(10). e016627–e016627. 23 indexed citations
14.
15.
Avery, Anthony, Claire Anderson, Heather Fortnum, et al.. (2011). Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technology Assessment. 15(20). 1–234, iii. 252 indexed citations
16.
Layton, Deborah, Moira Dryburgh, Thomas M. MacDonald, Saad Shakir, & Isla S. Mackenzie. (2011). Pilot Swine Flu Vaccination Active Surveillance Study: Final Results. Drug Safety. 34(10). 889–890.
17.
Layton, Deborah, et al.. (2010). New Postgraduate Qualifications in Pharmacovigilance from the Drug Safety Research Unit in the UK. Drug Safety. 34(1). 89–91. 2 indexed citations
18.
Mackenzie, Isla S., Moira Dryburgh, Derek Rutherford, et al.. (2010). Participation of General Practices in a Swine Flu Vaccination Study. Drug Safety. 33(10). 911–911. 1 indexed citations
19.
Biswas, Pipasha, Lynda V. Wilton, & Saad Shakir. (2003). The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13 554 patients in England. Journal of Psychopharmacology. 17(1). 121–126. 37 indexed citations
20.
Ahmed, Tanveer, et al.. (1996). Heterogeneity of Allergic Airway Responses in Sheep: Differences in Signal Transduction?. American Journal of Respiratory and Critical Care Medicine. 154(4). 843–849. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gianluca Trifirò Breakdown of academic impact, for papers by Eugène van Puijenbroek Breakdown of academic impact, for papers by Maryse Lapeyre‐Mestre Breakdown of academic impact, for papers by Alexandre Pariente Breakdown of academic impact, for papers by Ron M. C. Herings Breakdown of academic impact, for papers by Annie Fourrier‐Réglat Breakdown of academic impact, for papers by Inés Ruiz Breakdown of academic impact, for papers by E A Roberts Breakdown of academic impact, for papers by Bernard Bégaud Breakdown of academic impact, for papers by E Janecek
Rankless by CCL
2026